Apyx Medical (NASDAQ:APYX) Upgraded at Zacks Research

Apyx Medical (NASDAQ:APYX) was upgraded by research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright started coverage on shares of Apyx Medical in a research note on Monday. They set a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $4.42 on Tuesday. The firm has a market capitalization of $185.25 million, a PE ratio of -20.09 and a beta of 1.37. Apyx Medical has a 1 year low of $1.59 and a 1 year high of $5.08. The company has a current ratio of 5.80, a quick ratio of 4.79 and a debt-to-equity ratio of 2.68. The firm’s fifty day simple moving average is $4.22 and its 200 day simple moving average is $3.89.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative return on equity of 88.47% and a negative net margin of 16.40%.The company had revenue of $12.49 million during the quarter, compared to analyst estimates of $10.53 million. On average, sell-side analysts anticipate that Apyx Medical will post -0.21 EPS for the current year.

Institutional Investors Weigh In On Apyx Medical

A number of hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC acquired a new stake in Apyx Medical in the 1st quarter valued at about $255,000. Renaissance Technologies LLC lifted its position in shares of Apyx Medical by 37.2% during the first quarter. Renaissance Technologies LLC now owns 302,395 shares of the company’s stock worth $1,116,000 after purchasing an additional 82,000 shares in the last quarter. Sei Investments Co. lifted its position in shares of Apyx Medical by 298.6% during the first quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock worth $2,208,000 after purchasing an additional 448,174 shares in the last quarter. Nwam LLC bought a new stake in shares of Apyx Medical during the first quarter valued at approximately $47,000. Finally, Hillsdale Investment Management Inc. grew its stake in shares of Apyx Medical by 84.4% during the first quarter. Hillsdale Investment Management Inc. now owns 174,300 shares of the company’s stock valued at $643,000 after purchasing an additional 79,800 shares during the last quarter. Institutional investors own 55.33% of the company’s stock.

Key Stories Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Apyx Medical and set a $7.00 price target, implying meaningful upside from current levels.
• Positive Sentiment: The firm’s forecasts show gradually improving earnings over the next several quarters, with losses expected to narrow from around ($0.06) per share in mid-2026 to about ($0.03) per share by Q4 2027.
• Neutral Sentiment: HC Wainwright’s full-year estimates still call for losses in FY2026 and FY2027, so the business has not yet been projected to turn profitable. Apyx Medical stock page

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.